Now that shareholders have voted for the deal, Bristol-Myers Squibb faces some serious pressure to prove its Celgene buyout will actually pay off. So it’s no wonder analysts demand to know just how BMS executives plan to deliver the “value
read morePatients treated with oral semaglutide demonstrated greater HbA1c reductions and weight loss. More: Novo Nordisk files for EU approval of Ozempic in type II diabetes Source: News
read moreThe method would work by analysing the genetic faults in a sample of their blood. More: Blood samples to help choose early phase clinical trials for cancer patients Source: News
read moreFewer than one in five would use a voice controlled clinical decision support system that was offered by pharma. More: Just 20% of physicians say AI has changed the way they practice Source: News
read moreOffice of National Statistics data shows that between 1997 and 2017, total healthcare expenditure increased from £54.5 billion to £177.4 billion. More: Experts ‘deeply concerned’ about NHS’ long-term sustainability Source: News
read moreThe study is designed to assess whether the addition of SCIB1 treatment will result in an improvement in the tumour response rate. More: UK regulatory approval for SCIB1 phase II advanced melanoma trial Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals